From disease basics to insightful analysis of market dynamics, Thyroid Carcinoma | Niche Disease Landscape & Forecast | United States, EU5 provides comprehensive disease coverage addressing critical aspects of the thyroid carcinoma pharmaceutical market based on detailed primary and secondary market research. Content includes a summary of disease etiology, pathophysiology, and drug targets; epidemiological projections, including estimates of drug treatment; a deep examination of current therapies and medical practice; a review of top unmet needs; a thorough pipeline assessment, including regulatory approval timing, positioning, and peak sales of key late-phase drugs; a top-line review of pertinent market access themes; and an epidemiology-based, bottom-up market forecast of key branded agents with supporting tables, figures, and methods.
Markets covered: United States, France, Germany, Italy, Spain, and the United Kingdom.
Primary research: 8 country-specific interviews with thought leaders.
Epidemiology: Diagnosed incident cases of thyroid carcinoma (WHO ICD-10 coding system and ICD-O3 histological classification of tumors) by disease stage (stage I, stage II, stage III, stage IVa, stage IVb, stage IVc) and thyroid carcinoma histologies (follicular, papillary, medullary, and anaplastic). Recurrent incident (distant metastatic) cases of thyroid carcinoma.
Population segments in market forecast: Locally advanced radioactive iodine-avid differentiated thyroid carcinoma; locally advanced and metastatic radioactive iodine-refractory differentiated thyroid carcinoma; locally advanced and metastatic symptomatic and/or progressive medullary thyroid carcinoma.
Emerging therapies: Phase III: 1 drug; Phase II: 9 drugs; coverage of selected Phase I products.